Please assess the completion status of the following clinical trial:

Trial Title: Double-Blind, Dose-Escalation Study of IDX184 in Chronic Hepatitis C Treatment-Naïve Subjects

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE1/PHASE2
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion criteria:~1. 18-65 years old~2. Subject of childbearing potential must agree to use a consistent form of an acceptable double-barrier method of birth control.~3. Plasma HCV RNA ≥ 5 log10 IU/mL~4. HCV genotype 1~Exclusion criteria:~1. Received prior antiviral treatment for hepatitis C infection~2. Subject is pregnant or breastfeeding~3. Body Mass Index (BMI) \> 32~4. Currently abusing alcohol or illicit drugs~5. Currently receiving methadone, buprenorphine or other drugs for the treatment of opioid addiction~6. Co-infected with hepatitis B virus (HBV, HBsAg positive) and/or human immunodeficiency virus (HIV)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Cohort A (Type: EXPERIMENTAL): Subjects randomized 8:2 (active:placebo) to receive one 25 milligrams (mg) capsule of IDX184 per day for 3 days. Fourteen days after treatment, subjects were offered a course of pegylated interferon and ribavirin according to local standard of care.
- Cohort B (Type: EXPERIMENTAL): Subjects randomized 8:2 (active:placebo) to receive two 25 mg capsules of IDX184 per day for 3 days. Fourteen days after treatment, subjects were offered a course of pegylated interferon and ribavirin according to local standard of care.
- Cohort C (Type: EXPERIMENTAL): Subjects randomized 8:2 (active:placebo) to receive three 25 mg capsules of IDX184 per day for 3 days. Fourteen days after treatment, subjects were offered a course of pegylated interferon and ribavirin according to local standard of care.
- Cohort D (Type: EXPERIMENTAL): Subjects randomized 8:2 (active:placebo) to receive four 25 mg capsules of IDX184 per day for 3 days. Fourteen days after treatment, subjects were offered a course of pegylated interferon and ribavirin according to local standard of care.

Based on this trial design, predict the completion outcome and termination type (if applicable).